In Lysando’s Artilysin tech, AiCuris sees means to evade antibiotic resistance

AiCuris believes it can bypass antibiotic resistance by using Lysando's platform to develop an array of phage-derived antibacterial proteins spanning broad and narrow

Read the full 238 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE